Records 1 - 4
| Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2022 Jun .
Tashakori Mehrnoosh, Khoury Joseph D, Routbort Mark J, Patel Keyur P, Wang Sa A, Ok Chi Young, El-Hussein Siba, Kanagal-Shamanna Rashmi, Luthra Rajyalakshmi, Hu Shimin, Lin Pei, Pemmaraju Naveen, Bose Prithviraj, Verstovsek Srdan, Bueso-Ramos Carlos E, Medeiros L Jeffrey, Loghavi San
| Evaluation of clinical and laboratory findings with JAK2 V617F mutation as an independent variable in essential thrombocytosis.
Molecular biology reports 2014 Oct 41 (10): 6737-42.
Cetin Güven, Ozkan Tuba, Turgut Seda, Ali Cikrikcioglu M, Cem Ar M, Ayer Mesut, Unlu Ayhan, Celik Sevda Rabia, Sekin Yahya, Karatoprak Cuma
| Impact of JAK2 V617F mutation on hemogram variation in patients with non-reactive elevated platelet counts.
PloS one 2013 8 (2): e57856.
Zhou Juan, Ye Yuanxin, Zeng Shugen, Zhou Yi, Mao Zhigang, Song Xingbo, Ying Binwu, Lu Xiaojun, Jiang Hong, Wang Lanl
| JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia.
Journal of clinical pathology 2009 Sep 62 (9): 798-801.
Pich A, Riera L, Sismondi F, Godio L, Davico Bonino L, Marmont F, Francia di Celle